CL2022001486A1 - Formulaciones de anticuerpos anti-pd-l1. - Google Patents

Formulaciones de anticuerpos anti-pd-l1.

Info

Publication number
CL2022001486A1
CL2022001486A1 CL2022001486A CL2022001486A CL2022001486A1 CL 2022001486 A1 CL2022001486 A1 CL 2022001486A1 CL 2022001486 A CL2022001486 A CL 2022001486A CL 2022001486 A CL2022001486 A CL 2022001486A CL 2022001486 A1 CL2022001486 A1 CL 2022001486A1
Authority
CL
Chile
Prior art keywords
formulations
antibody formulations
liquid pharmaceutical
antibody
methods
Prior art date
Application number
CL2022001486A
Other languages
English (en)
Inventor
Ada Hui
Judith Zhu-Shimoni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2022001486A1 publication Critical patent/CL2022001486A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona formulaciones farmacéuticas líquidas que comprenden un anticuerpo anti-PD-L1, tales como formulaciones farmacéuticas líquidas para la administración subcutánea. La invención también proporciona procedimientos para fabricar dichas formulaciones y procedimientos de uso de dichas formulaciones.
CL2022001486A 2019-12-09 2022-06-06 Formulaciones de anticuerpos anti-pd-l1. CL2022001486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962945730P 2019-12-09 2019-12-09

Publications (1)

Publication Number Publication Date
CL2022001486A1 true CL2022001486A1 (es) 2023-01-20

Family

ID=74206149

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022001486A CL2022001486A1 (es) 2019-12-09 2022-06-06 Formulaciones de anticuerpos anti-pd-l1.
CL2023001140A CL2023001140A1 (es) 2019-12-09 2023-04-20 Formulaciones de anticuerpos anti-pd-l1

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023001140A CL2023001140A1 (es) 2019-12-09 2023-04-20 Formulaciones de anticuerpos anti-pd-l1

Country Status (15)

Country Link
US (1) US20230039268A1 (es)
EP (1) EP4073120A2 (es)
JP (1) JP2023504748A (es)
KR (1) KR20220113414A (es)
CN (1) CN114787191A (es)
AU (1) AU2020399619A1 (es)
BR (1) BR112022011228A2 (es)
CA (1) CA3158987A1 (es)
CL (2) CL2022001486A1 (es)
CR (1) CR20220322A (es)
IL (1) IL293580A (es)
MX (1) MX2022006784A (es)
PE (1) PE20221281A1 (es)
TW (1) TW202128223A (es)
WO (1) WO2021118930A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313658A (en) 2021-12-22 2024-08-01 Genentech Inc Clinical formulations of anti-TIGIT antibodies
WO2024126750A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2312208C (en) 1997-12-05 2011-01-25 The Scripps Research Institute Humanization of murine antibody
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PL2163643T3 (pl) 2003-03-05 2015-06-30 Halozyme Inc Rozpuszczalna glikoproteina o aktywności hialuronidazy (sHASEGP), sposób jej wytwarzania, zastosowania oraz zawierające ją kompozycje farmaceutyczne
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AR097791A1 (es) 2013-09-27 2016-04-13 Genentech Inc Formulaciones de anticuerpos anti-pdl1
MA47313B1 (fr) * 2017-01-17 2020-12-31 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2

Also Published As

Publication number Publication date
CN114787191A (zh) 2022-07-22
US20230039268A1 (en) 2023-02-09
CR20220322A (es) 2022-07-28
MX2022006784A (es) 2022-07-11
IL293580A (en) 2022-08-01
PE20221281A1 (es) 2022-09-05
KR20220113414A (ko) 2022-08-12
TW202128223A (zh) 2021-08-01
AU2020399619A1 (en) 2022-06-09
BR112022011228A2 (pt) 2022-10-11
JP2023504748A (ja) 2023-02-06
EP4073120A2 (en) 2022-10-19
WO2021118930A2 (en) 2021-06-17
CA3158987A1 (en) 2021-06-17
WO2021118930A3 (en) 2021-08-19
CL2023001140A1 (es) 2023-10-06

Similar Documents

Publication Publication Date Title
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
CO2020001983A2 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39
SV2018005710A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CO2019006059A2 (es) Anticuerpos monoclonales anti-alfa-sinucleína para prevenir la agregación de tau
EA202191632A1 (ru) Ахромосомные динамические активные системы
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
CL2018003527A1 (es) Conjugados de anticuerpo anti-egfr y fármaco.
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
GT201700063A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CL2021000493A1 (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
PH12020551716A1 (en) Anti-ror antibody constructs
BR112018070603A2 (pt) formulações líquidas de fosfaplatina